Adawi Kamal sold $14K of FATE

Adawi Kamal (Chief Financial Officer) sold 6,582 shares of FATE THERAPEUTICS INC (FATE) at $2.05 on 2026-11-03.

Original reporting
SEC EDGAR · Adawi Kamal
Published Nov 4, 2026, 9:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 9:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$FATE
Bearish
medium confidence
Mentioned
$FATE
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$FATEBearishLow
01

Why it matters

The disclosed sale is modest and unlikely to move the stock significantly, but adds to the flow of insider activity data.

02

Market read

Small insider sell; minimal immediate trading impact.

03

What to watch

No 10b5-1 plan; CFO may be diversifying holdings.

Relevance 3/10Novelty 3/10Timing: post-market filing

Background

Form 4 filing discloses insider transactions; investors monitor CFO sales for signals.

Company-level read

Ticker impact

$FATEBearishMedium confidence
Context

CFO Adawi Kamal sold 6,582 shares for $13.5K, reducing his stake to 93,418 shares.

Expected impact

likely modest pressure as the market prices in the insider sale.

Evidence & confidence

The sale is small relative to total holdings and market cap, but CFO insider activity is watched by traders.

Market effects

Limited impact on biotech sector; typical insider sale.

None

None

Counterpoint

The sale could be routine portfolio rebalancing, not a red flag.

Key entities

  • Fate Therapeutics Inc.

    Biotech firm developing cellular immunotherapies.

  • Adawi Kamal

    Chief Financial Officer of Fate Therapeutics.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$FATEHigh

Fate Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates

FATE THERAPEUTICS INC (FATE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Fate Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates Safety profile presented at ASN Kidney Week 2026 across 29 autoimmune patients treated with a single dose of FT819 and fludarabine-free, less-intensive conditioning continues to be fa

$FATEMed

Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN

FATE THERAPEUTICS INC (FATE) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN $15.0 Million Award to Support Advancement of RECLAIM-LN, a Phase 2 Potentially Registrational Trial of FT819 Off-the-Shelf CAR T-Cell Thera

$FATEMedAI 8/10

Fate Therapeutics, Inc.: Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis

Fate Therapeutics (NASDAQ: FATE) dosed the first patient in its Phase 2 potentially registrational RECLAIM-LN trial of FT819 for refractory moderate-to-severe SLE with Class III or IV lupus nephritis. The single-arm study targets about 53 patients, with complete renal response at Week 26 as the primary endpoint. Enrollment is expected to finish in 15-18 months, by 1H2028.

$FATEMed

Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates

FATE THERAPEUTICS INC (FATE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates First lupus nephritis patient dosed in RECLAIM-LN, a Phase 2 potentially registrational trial utilizing FT819, an iPSC-derived, off-the-shelf CAR T-cell therapy; patient was treated